Search Results for "Rituximab Patent"

21:25 EDT 24th October 2016 | BioPortfolio

Matching Channels

CD20 Antibodies

The chimeric anti-CD20 antibody rituximab (Rituxan & MabThera) from Biogen Idec and Genentech/Roche is one of the world’s commercially most successful antibodies (2007 sales of over US$ 5 bl...

Biosuperior Antibodies

After biosimilar versions of therapeutic proteins have become reality in Europe and in the US, now it’s the turn of therapeutic antibodies to be in the line of fire. Patents of the first wave of...


India, in the Asian subcontinent is the world’s fourth largest producer of pharmaceuticals, and is thought as one of the most promising biotech markets in the world. Several important steps ...

Tumor Necrosis Factor TNF Products

Tumor Necrosis Factor (TNF) and TNF receptor antagonists and agonists used to treat TNF-mediated inflammatory diseases such as rheumatoid arthritis or to treat cancer. TNF blockers are the commerc...

Matching News

Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental setting

Rituximab has broad and increasing application in rheumatic diseases. It is known from lymphoma studies that natural killer (NK) cells can lyse rituximab-coated transformed B cells. However, the role ...

EMA Accepts Submission for Rituximab Biosimilar

​Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Medicines Agency has accepted their Marketing Authorization Application for a biosimilar to Roche...

Rituximab biosimilar shows pharmacokinetic bioequivalence in patients with RA

GP2013, a proposed rituximab biosimilar, demonstrated pharmacokinetic bioequivalence to rituximab in patients with rheumatoid arthritis, according to results presented at the EULAR Annual Congress.Res...

Rituximab for Thrombotic Thrombocytopenic Purpura

Adding rituximab to plasma exchange and steroids improved relapse-free survival in a nonrandomized trial.

ECTRIMS: Rituximab Beats MS Drugs in Swedish Registry Study (CME/CE)

(MedPage Today) -- Finds survival advantage for rituximab over fingolimod and natalizumab

Rituximab decreased disease activity in patients with severe or refractory SLE

Treatment of systemic lupus erythematosus with rituximab effectively decreased disease activity with a low incidence of adverse effects in patients with severe or refractory disease, according to resu...

Rituximab Improves Outcomes in Adult Acute Lymphoblastic Leukemia

Adding rituximab to ALL chemotherapy improved event-free survival in patients with CD20-positive, Ph-negative ALL.

Rituximab for ALL Subset Improves Outcomes

Adding rituximab to standard chemo significantly improved 2-year event-free survival in patients with CD20-positive disease. Medscape Medical News

Matching PubMed Articles

Searching bioremediation patents through Cooperative Patent Classification (CPC).

Patent classification systems have traditionally evolved independently at each patent jurisdiction to classify patents handled by their examiners to be able to search previous patents while dealing wi...

Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries.

Rituximab is a standard treatment for non-Hodgkin lymphoma. The SABRINA trial (NCT01200758) showed that a subcutaneous (SC) rituximab formulation did not compromise efficacy or safety compared with in...

Is rituximab sub-optimally dosed in indolent B cell lymphoma?

Rituximab pharmacokinetics are affected by gender, age and weight and can affect outcomes in aggressive B cell lymphoma. Less is known about the pharmacokinetics of rituximab in indolent B cell lympho...

Rituximab-induced lung disease.

Pulmonary toxicity is a rare complication of Rituximab therapy. Although Rituximab is relatively safe and can be administered in an outpatient setting, Rituximab-associated lung disease has been repor...

Rituximab Use in Pediatric Dermatology.

Rituximab, an anti CD20 monoclonal antibody leading to transitory B cell depletion, is used to treat a wide variety of immune system tumors and immune mediated diseases. While most of data supporting ...

Search Whole site using Google

Quick Search
Advertisement Advertisement